1681 — Consun Pharmaceutical Share Price
Last trade - 00:00- HK$5.03bn
- HK$1.97bn
- CNY2.59bn
- 98
- 87
- 75
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.57 | ||
| PEG Ratio (f) | 0.39 | ||
| EPS Growth (f) | 13.33% | ||
| Dividend Yield (f) | 8.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.33 | ||
| Price to Free Cashflow | 5.97 | ||
| Price to Sales | 1.67 | ||
| EV to EBITDA | 1.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.09% | ||
| Return on Equity | 23.91% | ||
| Operating Margin | 34.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,728.26 | 1,752.83 | 2,044.66 | 2,339.65 | 2,590.11 | 2,920 | 3,316 | 7.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -48.59 | +122.96 | +20.46 | +17.43 | +13.78 | +8.89 | +14.95 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Consun Pharmaceutical Group Ltd is a company principally engaged in manufacturing and sales of pharmaceutical products. The Company operates its businesses through two segments. Consun Pharmaceutical segment is mainly engaged in manufacturing and sells of modern Chinese medicines and medical contrast medium. Yulin Pharmaceutical segment is mainly involved in manufacturing and sells of traditional Chinese medicines. The Company's products include kidney medicines, gynaecology and paediatrics medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines and others. The Company mainly operates its businesses in the domestic market.
Directors
- Meng An CHM (49)
- Quan Li CEO (55)
- Hanxing Xu GMG (27)
- Quan Zhu EDR (75)
- Lanfen Fang OTH (52)
- Pei Cheng Fang OTH (36)
- Bihua Yao OTH (51)
- Shangwen Zhou OTH (45)
- Chi Ming Yau SEC (50)
- Lihua Zhang NED (44)
- Yujun Chen NID (39)
- Zhongshi Feng NID (56)
- Yuanfu Su NID (69)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 13th, 2010
- Public Since
- December 19th, 2013
- No. of Employees
- 3,178
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 844,889,255
- Address
- 71 Dongpeng Avenue, East Section, GUANGZHOU, 510760
- Web
- http://www.chinaconsun.com/
- Phone
- +86 2082016888
- Auditors
- KPMG LLP
Upcoming Events for 1681
Similar to 1681
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 20:33 UTC, shares in Consun Pharmaceutical are trading at HK$5.95. This share price information is delayed by 15 minutes.
Shares in Consun Pharmaceutical last closed at HK$5.95 and the price had moved by +21.41% over the past 365 days. In terms of relative price strength the Consun Pharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +13.25% over the past year.
The overall consensus recommendation for Consun Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Consun Pharmaceutical dividend yield is 10.2% based on the trailing twelve month period.
Last year, Consun Pharmaceutical paid a total dividend of CNY0.55, and it currently has a trailing dividend yield of 10.2%.Looking ahead, the next dividend pay date is 2024-09-20.
We do not have data on when Consun Pharmaceutical is to next pay dividends. The historic dividend yield on Consun Pharmaceutical shares is currently 10.2%.
To buy shares in Consun Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$5.95, shares in Consun Pharmaceutical had a market capitalisation of HK$5.03bn.
Here are the trading details for Consun Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1681
Based on an overall assessment of its quality, value and momentum Consun Pharmaceutical is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Consun Pharmaceutical is HK$7.83. That is 31.57% above the last closing price of HK$5.95.
Analysts covering Consun Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY1.07 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Consun Pharmaceutical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +4.35%.
As of the last closing price of HK$5.95, shares in Consun Pharmaceutical were trading +10.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Consun Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 4.57. The shares last closed at HK$5.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Consun Pharmaceutical's management team is headed by:
- Meng An - CHM
- Quan Li - CEO
- Hanxing Xu - GMG
- Quan Zhu - EDR
- Lanfen Fang - OTH
- Pei Cheng Fang - OTH
- Bihua Yao - OTH
- Shangwen Zhou - OTH
- Chi Ming Yau - SEC
- Lihua Zhang - NED
- Yujun Chen - NID
- Zhongshi Feng - NID
- Yuanfu Su - NID